-
公开(公告)号：US08361795B2
公开(公告)日：2013-01-29
申请号：US12521135
申请日：2007-12-21
Applicant: Zuze Wu , Bingxing Shi , Chunping Cui , Shaojun Du , Danli Wu
Inventor： Zuze Wu , Bingxing Shi , Chunping Cui , Shaojun Du , Danli Wu
IPC: C12N5/06 , C12N5/08 , A61K38/16 , A61K31/70 , C07K14/475
CPC classification number: C07K14/4753 , A61K31/7088 , A61K38/00
Abstract: Provided are a hepatopoietin PCn (HPPCn) and its homologous proteins, which can promote hepatocyte proliferation in vitro, promote liver regeneration in vivo, inhibit the growth of tumor cells and promote the apoptosis of tumor cells. The hepatopoietin PCn (HPPCn) and its homologous proteins are useful for the treatment of acute and chronic liver injury, or the treatment of liver fibrosis.
Abstract translation: 提供了一种促肝细胞生成素PCn（HPPCn）及其同源蛋白，可以在体外促进肝细胞增殖，促进体内肝脏再生，抑制肿瘤细胞的生长，促进肿瘤细胞的凋亡。 肝细胞生成素PCn（HPPCn）及其同源蛋白可用于治疗急性和慢性肝损伤或治疗肝纤维化。
-
公开(公告)号：US20100144628A1
公开(公告)日：2010-06-10
申请号：US12521135
申请日：2007-12-21
Applicant: Zuze Wu , Bingxing Shi , Chunping Cui , Shaojun Du , Danli Wu
Inventor： Zuze Wu , Bingxing Shi , Chunping Cui , Shaojun Du , Danli Wu
IPC: A61K38/17 , C07K14/435 , C07H21/00 , A61K31/7052 , A61P1/16 , A61P35/00
CPC classification number: C07K14/4753 , A61K31/7088 , A61K38/00
Abstract: Provided are a hepatopoietin PCn (HPPCn) and its homologous proteins, which can promote hepatocyte proliferation in vitro, promote liver regeneration in vivo, inhibit the growth of tumor cells and promote the apoptosis of tumor cells. The hepatopoietin PCn (HPPCn) and its homologous proteins are useful for the treatment of acute and chronic liver injury, or the treatment of liver fibrosis.
Abstract translation: 提供了一种促肝细胞生成素PCn（HPPCn）及其同源蛋白，可以在体外促进肝细胞增殖，促进体内肝脏再生，抑制肿瘤细胞的生长，促进肿瘤细胞的凋亡。 肝细胞生成素PCn（HPPCn）及其同源蛋白可用于治疗急性和慢性肝损伤或治疗肝纤维化。
-
3.发明授权Bifunctional fusion protein with thrombolytic and anticoagulant activities and uses thereof 有权具有溶栓和抗凝活性的双功能融合蛋白及其用途公开(公告)号：US08212003B2
公开(公告)日：2012-07-03
申请号：US10526682
申请日：2003-09-03
Applicant: Bingxing Shi , Zuze Wu , Aiping Yu , Chunna Dong
Inventor： Bingxing Shi , Zuze Wu , Aiping Yu , Chunna Dong
CPC classification number: C07K14/47 , A61K38/00 , C07K14/31 , C07K14/815 , C07K19/00 , C07K2319/00 , C07K2319/50 , C12N9/6459 , C12N15/62 , C12Y304/21069
Abstract: This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an anticoagulant protein and a protein molecule having plasminogen-activating activity, wherein said two proteins are linked together via a linker peptide, which can be recognized and cleaved by blood coagulation factors. The application also relates to the medical use of said fusion protein, and to the use of the linker peptide which can be recognized by blood coagulation factor in linking a thrombolytic protein and an anticoagulation protein.
Abstract translation: 本申请涉及融合蛋白，其由溶血栓蛋白，抗凝血蛋白和接头肽组成。 特别地，融合蛋白由抗凝血蛋白和具有纤溶酶原激活活性的蛋白质分子组成，其中所述两种蛋白质通过接头肽连接在一起，可通过凝血因子识别和切割。 本申请还涉及所述融合蛋白的医学用途，以及使用凝血因子可以识别血液凝固蛋白和抗凝蛋白的接头肽。
-
4.发明申请公开(公告)号：US20060127389A1
公开(公告)日：2006-06-15
申请号：US10526682
申请日：2003-09-03
Applicant: Bingxing Shi , Zuze Wu , Aiping Yu , Chunna Dong
Inventor： Bingxing Shi , Zuze Wu , Aiping Yu , Chunna Dong
CPC classification number: C07K14/47 , A61K38/00 , C07K14/31 , C07K14/815 , C07K19/00 , C07K2319/00 , C07K2319/50 , C12N9/6459 , C12N15/62 , C12Y304/21069
Abstract: This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an anticoagulant protein and a protein molecule having plasminogen-activating activity, wherein said two proteins are linked together via a linker peptide, which can be recognized and cleaved by blood coagulation factors. The application also relates to the medical use of said fusion protein, and to the use of the linker peptide which can be recognized by blood coagulation factor in linking a thrombolytic protein and an anticoagulation protein.
Abstract translation: 本申请涉及融合蛋白，其由溶血栓蛋白，抗凝血蛋白和接头肽组成。 特别地，融合蛋白由抗凝血蛋白和具有纤溶酶原激活活性的蛋白质分子组成，其中所述两种蛋白质通过接头肽连接在一起，可通过凝血因子识别和切割。 本申请还涉及所述融合蛋白的医学用途，以及使用凝血因子可以识别血液凝固蛋白和抗凝蛋白的接头肽。
-
-
-
Search Results
4
records
(took 0.007 seconds)
